EP1792988A3 - Compounds and methods for therapy and diagnosis of lung cancer - Google Patents

Compounds and methods for therapy and diagnosis of lung cancer Download PDF

Info

Publication number
EP1792988A3
EP1792988A3 EP06023711A EP06023711A EP1792988A3 EP 1792988 A3 EP1792988 A3 EP 1792988A3 EP 06023711 A EP06023711 A EP 06023711A EP 06023711 A EP06023711 A EP 06023711A EP 1792988 A3 EP1792988 A3 EP 1792988A3
Authority
EP
European Patent Office
Prior art keywords
lung cancer
compounds
diagnosis
methods
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06023711A
Other languages
German (de)
French (fr)
Other versions
EP1792988A2 (en
Inventor
Steven G. Reed
Tongtong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/040,984 external-priority patent/US6210883B1/en
Priority claimed from US09/123,912 external-priority patent/US6312695B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to EP08165424A priority Critical patent/EP2003201A3/en
Priority claimed from EP99912607A external-priority patent/EP1064372B1/en
Publication of EP1792988A2 publication Critical patent/EP1792988A2/en
Publication of EP1792988A3 publication Critical patent/EP1792988A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Compounds and methods for the treatment and diagnosis of lung cancer are provided. The inventive compounds include polypeptides containing at least a portion of a lung tumour protein. Vaccines and pharmaceutical compositions for immunotherapy of lung cancer comprising such peptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive polypeptides.
EP06023711A 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer Withdrawn EP1792988A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08165424A EP2003201A3 (en) 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4080298A 1998-03-18 1998-03-18
US09/040,984 US6210883B1 (en) 1998-03-18 1998-03-18 Compounds and methods for diagnosis of lung cancer
US12393398A 1998-07-27 1998-07-27
US09/123,912 US6312695B1 (en) 1998-03-18 1998-07-27 Compounds and methods for therapy of lung cancer
EP99912607A EP1064372B1 (en) 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP99912607A Division EP1064372B1 (en) 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08165424A Division EP2003201A3 (en) 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer

Publications (2)

Publication Number Publication Date
EP1792988A2 EP1792988A2 (en) 2007-06-06
EP1792988A3 true EP1792988A3 (en) 2007-08-22

Family

ID=45569967

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08165424A Withdrawn EP2003201A3 (en) 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer
EP06023711A Withdrawn EP1792988A3 (en) 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08165424A Withdrawn EP2003201A3 (en) 1998-03-18 1999-03-17 Compounds and methods for therapy and diagnosis of lung cancer

Country Status (3)

Country Link
EP (2) EP2003201A3 (en)
KR (1) KR20010041992A (en)
AR (1) AR020318A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002552A1 (en) * 1994-07-19 1996-02-01 Cytoclonal Pharmaceutics, Inc. Lung cancer marker
WO1996030389A1 (en) * 1995-03-29 1996-10-03 Millenium Pharmaceuticals, Inc. Compositions for the diagnosis, prevention, and treatment of tumor progression
WO1999044620A1 (en) * 1998-03-03 1999-09-10 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPS59116229A (en) 1982-12-24 1984-07-05 Teijin Ltd Cell toxicity complex and its preparation
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
JPH04505547A (en) 1988-01-04 1992-10-01 イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー Multi-step affinity method for isolating specific cells from cell mixtures
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
DK0465529T3 (en) 1989-03-21 1998-10-05 Vical Inc Expression of exogenous polynucleotide sequences in a vertebrate
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
DE69126620T2 (en) 1990-10-18 1997-10-02 Cellpro Inc DEVICE AND METHOD FOR SEPARATING PARTICLES BY MEANS OF A BENDABLE VESSEL
WO1992020068A1 (en) 1991-05-07 1992-11-12 Sophos Technologic Fast memory system employing mostly good memories
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
WO1996038591A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002552A1 (en) * 1994-07-19 1996-02-01 Cytoclonal Pharmaceutics, Inc. Lung cancer marker
WO1996030389A1 (en) * 1995-03-29 1996-10-03 Millenium Pharmaceuticals, Inc. Compositions for the diagnosis, prevention, and treatment of tumor progression
WO1999044620A1 (en) * 1998-03-03 1999-09-10 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRASS N ET AL: "Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces animmune response in squamous cell lung carcinoma", HUMAN MOLECULAR GENETICS., vol. 6, no. 1, January 1997 (1997-01-01), OXFORD UNIVERSITY PRESS, SURREY., GB, pages 33 - 39, XP002112603, ISSN: 0964-6906 *
FINCH J ET AL.: "Identification of a cloned sequence activated during multi-stage carcinogenesis in mouse skin", CARCINOGENESIS, vol. 12, no. 8, August 1991 (1991-08-01), pages 1519 - 1522, XP002112604 *

Also Published As

Publication number Publication date
EP1792988A2 (en) 2007-06-06
AR020318A1 (en) 2002-05-08
EP2003201A2 (en) 2008-12-17
EP2003201A3 (en) 2008-12-31
KR20010041992A (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
EP1876241A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL153996A0 (en) Polypeptides containing at least a portion of an ovarian carcinoma protein, polynucleotides encoding the same and pharmaceutical compositions containing the same
MX344216B (en) Genetic products differentially expressed in tumors and the use thereof.
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
WO1996040039A3 (en) Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
EP1964850A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
EP2003201A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer
WO2004015390A3 (en) Lung cancer target proteins and use thereof
HU9601139D0 (en) Metal-bonding cystein-free peptides for diagnosis and therapy, process for producing them and pharmaceutical preparations containing these compounds
WO1999054466A3 (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
WO2003042700A3 (en) Breast cancer associated polypeptide
CO5050254A1 (en) COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER DE PULMON
WO2000065053A3 (en) Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1064372

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: REED, STEVEN G.

Inventor name: WANG, TONGTONG

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105014

Country of ref document: HK

17P Request for examination filed

Effective date: 20080211

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20080526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081206

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105014

Country of ref document: HK